Jefferies is the sole bookrunner; Baird, JMP Securities also to assist
By Devika Patel
Knoxville, Tenn., June 30 – Minerva Neurosciences, Inc. said it priced its $32.73 million initial public sale of stock with a $4.91 million greenshoe. The deal was announced on April 9.
The company will sell 5,454,545 common shares at $6.00 per share.
Jefferies LLC is the bookrunner.
Settlement is expected July 7.
Proceeds will be used for clinical development, debt repayment, working capital and general corporate purposes.
The clinical-stage biopharmaceutical company is based in Cambridge, Mass. The company intends to list its common stock on the Nasdaq under the symbol “NERV.”
| Issuer: | Minerva Neurosciences, Inc.
|
| Issue: | Common stock
|
| Amount: | $32,727,270
|
| Greenshoe: | $4,909,086
|
| Shares: | 5,454,545
|
| Price: | $6.00
|
| Warrants: | No
|
| Bookrunner: | Jefferies LLC
|
| Co-managers: | Robert W. Baird & Co. Inc. and JMP Securities LLC
|
| Announcement date: | April 9
|
| Pricing date: | June 30
|
| Settlement date: | July 7
|
| Stock symbol: | Nasdaq: NERV
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
